<DOC>
	<DOCNO>NCT00004259</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy , temozolomide , carmustine , lomustine , use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : This randomized phase III trial study radiation therapy temozolomide see well work compare radiation therapy carmustine lomustine treat patient anaplastic astrocytoma mixed glioma .</brief_summary>
	<brief_title>Radiation Therapy Combined With Chemotherapy Treating Patients With Anaplastic Astrocytoma Mixed Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival time tumor progression patient anaplastic astrocytoma mixed glioma treat radiotherapy combine temozolomide vs carmustine lomustine v temozolomide carmustine ( arm discontinue 8/15/02 ) . - Compare relative toxic effect regimens patient . - Correlate molecular analysis overall survival time tumor progression patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 50 vs 50 ) , Karnofsky performance status ( 60-80 % vs 90-100 % ) , prior surgery ( biopsy v resection ) . Phase I ( close 8/15/02 ) - Prior initiate randomization 1 3 treatment arm phase III , 15 patient accrue arm III . If 2 first 15 patient experience grade 3 bad pulmonary toxicity OR 5 first 15 patient experience grade 4-5 thrombocytopenia/neutropenia , arm III treatment discontinue . Phase III - Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy 5 day week 6 week . Patients receive oral temozolomide day 1-5 first week radiotherapy . Chemotherapy repeat every 4 week total 12 course . - Arm II : Patients undergo radiotherapy arm I . Patients receive carmustine IV lomustine IV 1-2 hour day 1-3 first week radiotherapy second course day 56-58 . Chemotherapy repeat every 8 week total 6 course . - Arm III ( discontinue 8/15/02 ) : Patients undergo radiotherapy arm I . Patients receive carmustine IV lomustine IV 3 hour day 5 oral temozolomide ( 2 hour completion carmustine lomustine infusion ) day 1-5 first week radiotherapy . Combination chemotherapy repeat every 8 week 6 course . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrued phase I study total 454 patient ( 227 per treatment arm ) accrue phase III study within 4 year . ( Phase I close 8/15/02 )</detailed_description>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unifocal anaplastic astrocytoma mixed glioma , include follow : Anaplastic oligoastrocytoma Mixed oligodendroglial/astrocytic tumor Oligodendroglial component must great 25 % No vascular proliferation necrosis Increased cellularity , pleomorphism , nuclear atypia allow No tumor predominantly locate posterior fossa ( i.e. , brainstem cerebellum ) Patients prior biopsy proven low grade astrocytoma anaplastic astrocytoma prior radiotherapy chemotherapy also eligible Study therapy must begin within 6 week diagnosis No spinal cord tumor , spinal drop metastasis , metastases noncontiguous meninges Pathologic evidence local meningeal infiltration underlie tumor allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 1 year Hematopoietic : Hemoglobin least 10 g/dL Absolute neutrophil count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) less 2 time ULN Alkaline phosphatase less 2 time ULN Renal : Blood urea nitrogen great 25 mg/dL Creatinine le 1.5 time normal Pulmonary : No preexist lung disease , investigator 's opinion , would preclude administration carmustine lomustine completion therapy Other : No major medical illness psychiatric impairment would preclude study compliance No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix No known hypersensitivity 1 component carmustine , lomustine , temozolomide , dacarbazine , nitrosourea No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : See Disease Characteristics No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy brain head neck Surgery : Not specify Other : No concurrent anticancer treatment anaplastic astrocytoma recurrence detect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>